
RAPID: Etripamil Converts Two-Thirds of Recurrent PSVT Episodes After Ablation
James Ip, MD, discusses his new analysis of the RAPID portion of the phase 3 NODE-301 trial, which indicates the efficacy of etripamil in patients who have undergone an incomplete ablation.
Etripamil successfully converted roughly 66% of all episodes of
This analysis was presented by James Ip, MD, a professor and cardiologist at Weill Cornell Medicine, at the
“Most of the time, ablation is successful, but there are a few patients who still have recurrences,” Ip told HCPLive. “It could be due to a number of causes: the procedure could have failed to induce the arrhythmia they presented with, it could swell the tissue and not get rid of the circuit definitively, or the procedure could have been aborted, at which point clinicians may decide to manage it more conservatively with medications.”
The original RAPID study was actually the second part of the broader NODE-301 trial, which evaluated the efficacy of self-administered etripamil nasal spray in patients who experienced an episode of PSVT in an at-home setting. The RAPID portion of the trial included patients who did not use etripamil for a perceived PSVT episode prior to the Part 1 data cutoff, which occurred at the 150th positively adjudicated episode, as well as newly enrolled patients.2
Before randomization in the RAPID portion, all patients were given a test dose of etripamil 70 mg, followed by another dose 10 minutes later to evaluate tolerability and to train patients on study procedures. Following test dose administration, patients were randomly assigned in a 1:1 ratio to receive either etripamil or placebo. After administering etripamil for a perceived episode, patients could enter an open-label period during which they could treat a second episode.2
Among the 692 patients randomly assigned, 184 (99 assigned to etripamil and 85 assigned to placebo) self-administered the drug for atrioventricular-nodal-dependent PSVT, with diagnosis and timing both confirmed. Kaplan-Meier estimates showed that conversion rates by 30 minutes were 64% (63/99) with etripamil and 31% (26/85) with placebo. Treatment-emergent adverse events occurred in 50% of patients receiving etripamil and 11% in the placebo group.3
In the present analysis, Ip and colleagues examined the entire study population, noting that 255 patients (37%) received treatment for a perceived PSVT episode and 184 (27%) were adjudicated as confirmed PSVT. Prior ablation was reported in 46 of 692 enrolled patients, in 22 of 255 receiving treatment, and in 13 of 184 with confirmed PSVT. Among this last group, 8 of 99 patients receiving etripamil had prior ablation, as did 5 of 85 receiving placebo.1
The efficacy population included 11 patients with prior ablation, with a mean age of 50.9 +/- 16.5 years. Conversion to sinus rhythm within 30 minutes occurred in 4 of 6 etripamil recipients, versus 1 in 5 placebo recipients. Baseline use of oral atrioventricular (AV)-nodal acting drugs, namely calcium channel blockers or beta blockers, was reported in 3 of 6 etripamil recipients and in 3 of 5 placebo recipients. The team saw no distinct safety signals in these patients on continuous electrocardiogram recordings.1
Ultimately, Ip and colleagues concluded that etripamil nasal spray effectively converted the majority of PSVT episodes in patients with prior ablation, doing so within 30 minutes of self-administration. Although the team acknowledges that this population was small, the data are consistent with the broader phase 3 cohort. Ip and colleagues also suggest that etripamil should be further investigated as an alternative for patients with incomplete resolution after ablation in place of a potential repeat ablation.1
“This is why I love medicine – just being able to talk to a patient about their condition, to have this shared decision that we make together about how best to treat them,” Ip said. “We’re not stuck with only a few options anymore, where you either had to have another ablation or just live with the condition. This is a great alternative that does work, and we can be reassured that it is safe and effective.”
Editors’ Note: Ip reports disclosures with Milestone Pharmaceuticals, Abbott, Medtronic, and Boston Scientific.
References
Ip J, Dorian P, Mondesert B, et al. Use of Etripamil in the RAPID Study for Recurrent PSVT After Prior Ablation. Presented at the American Heart Association (AHA) Scientific Sessions 2026, Chicago, IL. November 6-9, 2026.
Milestone Pharmaceuticals, Inc. Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT). (NODE-301). ClinicalTrials.gov Identifier: NCT03464019. Updated July 12, 2024. Accessed November 19, 2026.
https://clinicaltrials.gov/study/NCT03464019 Stambler BS, Camm AJ, Alings M, et al. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (rapid): A multicentre, randomised trial. The Lancet. 2023;402(10396):118-128.
doi:10.1016/s0140-6736(23)00776-6
Related to this article








